glp-1 ghrelin How gut hormones shape reward: A systematic review of the role of and in human fMRI How gut hormones shape reward:

Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users

This guidance follows the FDAs approval of Wegovy (semaglutide) for an expanded indication to reduce the risk of major cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established cardiovascular disease (CVD) and who are either obese or overweight

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

[DOI] [PubMed] [Google Scholar] 2.Creutzfeldt W., The incretin concept today

Biomolecules, 15 (1), 41.

They do not act against a single addictive substance, they act against the craving that drives addictions